<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6122">
  <stage>Registered</stage>
  <submitdate>10/08/2016</submitdate>
  <approvaldate>10/08/2016</approvaldate>
  <nctid>NCT02864381</nctid>
  <trial_identification>
    <studytitle>Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma</studytitle>
    <scientifictitle>A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Subjects With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-001402-41</secondaryid>
    <secondaryid>GS-US-296-2013</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gastric Adenocarcinoma</healthcondition>
    <healthcondition>Gastroesophageal Junction Adenocarcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Oesophageal (gullet)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Andecaliximab
Treatment: drugs - Nivolumab

Experimental: Andecaliximab+nivolumab - Andecaliximab+ nivolumab for up to 2 years

Experimental: Nivolumab - Nivolumab for up to 2 years


Treatment: drugs: Andecaliximab
800 mg administered via intravenous (IV) infusion every 2 weeks

Treatment: drugs: Nivolumab
3 mg/kg administered via intravenous (IV) infusion every 2 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Objective Response Rate - Objective response rate will be determined from the participants' best response during treatment.</outcome>
      <timepoint>Up to 2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival - Progression free survival is defined as the interval from the date of randomization to the earlier of the first documentation of definitive disease progression or death from any cause.</outcome>
      <timepoint>Up to 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival - Overall survival is defined as the interval from date of randomization to death from any cause.</outcome>
      <timepoint>Up to 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response - Duration of response is defined as the interval from the date of the first response (complete response or partial response) is achieved to the earlier of the first documentation of definitive disease progression or death from any cause.</outcome>
      <timepoint>Up to 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Occurrence of Adverse Events and Laboratory Abnormalities During Treatment - The occurrence of adverse events and laboratory abnormalities will be presented as the percentage of participants who experience treatment-emergent adverse events or treatment-emergent laboratory abnormalities.</outcome>
      <timepoint>Up to 2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Histologically confirmed inoperable locally advanced or metastatic adenocarcinoma of
             the stomach or GEJ which have progressed on at least 1 prior systemic therapy or line
             of treatment for unresectable/metastatic disease

          -  Eastern Cooperative Oncology Group (ECOG) performance score of = 1

          -  Measurable disease according to RECIST v1.1

          -  Tumor sites that can be accessed for repeat biopsies

          -  Archival tumor tissue, preferably obtained from the most recent available biopsy;
             there must be adequate tissue for a PD-L1 stratification test, as assessed by central
             pathologist

          -  Individuals not receiving anticoagulant medication must have an international
             normalized ratio (INR) = 1.5 and activated partial thromboplastin (aPTT) = 1.5 x upper
             limit of normal (ULN)

          -  Required baseline laboratory data as outlined in protocol

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Individuals who have received only neoadjuvant or adjuvant therapy for gastric
             adenocarcinoma

          -  Radiotherapy within 28 days of randomization

          -  Uncontrolled intercurrent illness as outlined in protocol

          -  History of a concurrent or second malignancy except for those outlined in protocol

          -  Major surgery, within 28 days of first dose of study drug

          -  Known positive status for human immunodeficiency virus (HIV)

          -  Known acute or chronic-active infection with hepatitis B virus (HBV) or hepatitis C
             virus (HCV)

          -  Chronic daily treatment with oral corticosteroids (dose of &gt; 10 mg/day prednisone
             equivalent) or other immunosuppressive medications within 14 days of randomization

          -  Known or suspected central nervous system metastases

          -  Documented myocardial infarction or unstable/uncontrolled cardiac disease within 6
             months of randomization

          -  Serious systemic fungal, bacterial, viral, or other infection that is not controlled
             or requires intravenous antibiotics

          -  Current or history of pneumonitis or interstitial lung disease

          -  Active known or suspected autoimmune disease with exceptions noted in protocol.

          -  History of bone marrow, stem cell, or allogenic organ transplantation

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>144</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/08/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,TAS</recruitmentstate>
    <hospital> - Albury</hospital>
    <hospital> - Wahroonga</hospital>
    <hospital> - Douglas</hospital>
    <hospital> - Hobart</hospital>
    <postcode>2640 - Albury</postcode>
    <postcode>2076 - Wahroonga</postcode>
    <postcode>4818 - Douglas</postcode>
    <postcode>7000 - Hobart</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Hainaut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Oost-Vlaanderen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Vlaams Brabant</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Finist√®re</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Val-de-Marne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Forli-Cesena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Ligura</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Podkarpackie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sutton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edgbaston</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to evaluate and compare the efficacy of andecaliximab
      (GS-5745) in combination with nivolumab versus nivolumab alone in adults with recurrent
      gastric or gastroesophageal junction (GEJ) adenocarcinoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02864381</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gilead Study Director</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>